Shots: The US approval is based on MOMENTUM 3 trial results enrolling 1000 patients with NYHA Class IIIB or IV heart failure for a short-term endpoint of six months and a long-term endpoint of two years The study demonstrated survival rate 82.8% @ 2yrs., clotting of blood 1.1% @ 2yrs., stroke rate of 10 % […]Read More
